Tag Archives: Associated

FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes WHIPPANY, N.J.– July 9, 2021 (BUSINESS WIRE)– Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained… Read More »

FDA Approves Epidiolex (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex

FDA Approves Epidiolex (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex Print this page CARLSBAD, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., today announced the U.S.… Read More »

Poliomyelitis – Pipeline Review, H2 2019: Symptoms Include Fever, Fatigue, Headache, Vomiting, Stiffness in the Neck & Pain in the Limbs – ResearchAndMarkets.com – Associated Press

DUBLIN–(BUSINESS WIRE)–Jan 9, 2020– The “Poliomyelitis – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain… Read More »

Number of Headache-Free Days in Migraine Associated With Health-Related Outcomes – Clinical Pain Advisor

Patients with migraine who have more headache-free days experience less work productivity loss and activity impairment and lower healthcare resource utilization, according to study results published in Pain and Therapy. In this retrospective study, the survey responses of 62,000 adults from 5 European nations were examined; in particular, the data from 1569 individuals with migraine… Read More »

FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Print this page SUMMIT, N.J.–(BUSINESS WIRE) July 19, 2019 — Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the… Read More »